Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

Presentation TCT 2025

Joint Modelling for Death and Quality of Life: Worthy as a Primary Endpoint

Presenter: John A. Spertus

October 27, 2025

Presentation TCT 2024

Patient-Reported Outcomes are a True Measure of TTVI Value

Presenter: John Spertus

October 30, 2024

Presentation TCT 2024

Measuring the outcomes most important to patients: Quality-of-life assessment

Presenter: John Spertus

October 29, 2024

Presentation THT 2022

Using Precision Medicine in the ED to Triage Patients With Heart Failure Exacerbations

Presenter: John Spertus

February 02, 2022

Presentation TCT 2018

CMS Strategy and the Move to Value

Presenter: Peter L Duffy, Timothy D. Henry, John A. Spertus

September 24, 2018

Presentation TCT 2018

Data Analysis: The Big Three Trials - Decision CTO, EURO CTO, OPEN CTO

Presenter: John A. Spertus, Robert W. Yeh, Ajay J. Kirtane

September 24, 2018

Presentation TCT 2018

Patient-Centered Engagement in Trials: Case Example - ADAPTABLE

Presenter: John C Laschinger, J. Dawn Abbott, Lori M Ashby, Robert A. Byrne, David A. Cox, Mona Fiuzat, Christopher O'Connor, John A. Spertus, Susan Strong

September 22, 2018

Presentation TCT 2018

Increasing Emphasis on QOL Outcomes: From Patient Preference to Instrument Validation

Presenter: David J. Cohen, Sunil V. Rao, John A. Spertus

September 22, 2018

Presentation CTO 2018

The Perspective of a Noninvasive Cardiologist

Presenter: John A. Spertus

February 16, 2018

Presentation TCT 2017

CMS Strategy and the Move to Value

Presenter: Peter L Duffy, Hadley Wilson, John A. Spertus

October 31, 2017

Presentation TCT 2016

When Equipoise Exists: Is Unbiased, Informed Consent Possible?

Presenter: John A. Bittl, David J. Maron, John A. Spertus

November 01, 2016

Presentation TCT 2016

Quality-of-Life Measures as Valid Clinical Surrogates and Primary Endpoints in Randomized Trials: Why the Resistance?

Presenter: Roxana Mehran, Pascal Vranckx, John A. Spertus

October 30, 2016

Presentation TCT 2015

Incorporating Quality-of-Life and Patient-Oriented Outcomes in the Device Regulatory Approval Process

Presenter: Andrew Farb, Gregg W. Stone, John A. Spertus

October 14, 2015

Presentation TCT 2015

Keynote Lecture 2: The Case for (and the Arguments Against) Moving Quality-of-Life Assessment Front and Center in Clinical Trials

Presenter: Ajay J. Kirtane, Roxana Mehran, John A. Spertus

October 12, 2015

Presentation

Precision Medicine to Improve Use of Bleeding Avoidance Strategies and Reduce Bleeding in PCI

Presenter: John A. Spertus

April 03, 2015

Presentation TCT 2013

What Really Matters: Integrating Hard Endpoints (eg, Death, MI), Quality-of-Life Metrics, and Patient Preferences

Presenter: John Spertus

October 30, 2013

Presentation TCT 2013

Defining the Optimal Role of AUC in Your Cath Lab

Presenter: John Spertus

October 30, 2013

Presentation TCT 2013

Benefits of Revascularization in Improving Quality of Life in SIHD: Metrics, Magnitude and Patient Selection

Presenter: John Spertus

October 29, 2013

Presentation TCT 2013

Quantifying the Quality-of-Life Benefits of PCI in Stable Ischemic Heart Disease

Presenter: John Spertus

October 28, 2013

Presentation

Frequency, Predictors, and Consequences of Crossing Over to Revascularization Within 12 Months of Randomization to Optimal Medical Therapy in COURAGE

Presenter: John A. Spertus

July 17, 2013

Advertisement

Joint Modelling for Death and Quality of Life: Worthy as a Primary Endpoint

Patient-Reported Outcomes are a True Measure of TTVI Value

Measuring the outcomes most important to patients: Quality-of-life assessment

Using Precision Medicine in the ED to Triage Patients With Heart Failure Exacerbations

CMS Strategy and the Move to Value

Data Analysis: The Big Three Trials - Decision CTO, EURO CTO, OPEN CTO

Patient-Centered Engagement in Trials: Case Example - ADAPTABLE

Increasing Emphasis on QOL Outcomes: From Patient Preference to Instrument Validation

The Perspective of a Noninvasive Cardiologist

CMS Strategy and the Move to Value

When Equipoise Exists: Is Unbiased, Informed Consent Possible?

Quality-of-Life Measures as Valid Clinical Surrogates and Primary Endpoints in Randomized Trials: Why the Resistance?

Incorporating Quality-of-Life and Patient-Oriented Outcomes in the Device Regulatory Approval Process

Keynote Lecture 2: The Case for (and the Arguments Against) Moving Quality-of-Life Assessment Front and Center in Clinical Trials

Precision Medicine to Improve Use of Bleeding Avoidance Strategies and Reduce Bleeding in PCI

What Really Matters: Integrating Hard Endpoints (eg, Death, MI), Quality-of-Life Metrics, and Patient Preferences

Defining the Optimal Role of AUC in Your Cath Lab

Benefits of Revascularization in Improving Quality of Life in SIHD: Metrics, Magnitude and Patient Selection

Quantifying the Quality-of-Life Benefits of PCI in Stable Ischemic Heart Disease

Frequency, Predictors, and Consequences of Crossing Over to Revascularization Within 12 Months of Randomization to Optimal Medical Therapy in COURAGE

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content